Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 1.00 |
| ▸ | CDK1 | P06493 | 17/20 | 1.00 |
| ▸ | CDK4 | P11802 | 17/20 | 1.00 |
| ▸ | CDK7 | P50613 | 17/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 16/20 | 1.00 |
| ▸ | CCNH | P51946 | 16/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 15/20 | 1.00 |
| ▸ | CCND1 | P24385 | 15/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 13/20 | 1.00 |
| ▸ | CDK9 | P50750 | 7/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 4/20 | 1.00 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.75 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.75 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1374946 | 1.00 | CDK2 (1.00) | CDK2CDK1CDK4CDK7CCNE1 | |
| SCHEMBL1376524 | 1.00 | CDK2 (1.00) | CDK2CDK1CDK4CDK7CCNE1 | |
| SCHEMBL4488751 | 0.90 | CDK1 (1.00) | CDK2CDK1CDK4CDK7CCNE1 | |
| SCHEMBL3876741 | 0.90 | CDK1 (1.00) | CDK2CDK1CDK4CDK7CCNE1 | |
| SCHEMBL3876749 | 0.90 | CDK1 (1.00) | CDK2CDK1CDK4CDK7CCNE1 | |
| SCHEMBL1378096 | 0.87 | CDK2 (0.89) | CDK2CDK1CDK4CDK7CCNE1 | |
| SCHEMBL3944585 | 0.86 | CDK2 (1.00) | CDK2CDK1CDK4CDK7CCNE1 | |
| SCHEMBL31060362 | 0.86 | CDK2 (1.00) | CDK2CDK1CDK4CDK7CCNE1 | |
| SCHEMBL1379184 | 0.86 | CDK2 (1.00) | CDK2CDK1CDK4CDK7CCNE1 | |
| SCHEMBL3855548 | 0.86 | CDK2 (1.00) | CDK2CDK1CDK4CDK7CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4723858-B2 | — | — | 2011-07-13 | — | — | JP | claimed |
| US-20100143350-A1 | COMBINATION OF A PURINE-BASED CDK INHIBITOR WITH A TYROSINE KINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2010-06-10 | — | — | US | claimed |
| EP-2139486-A1 | COMBINATION OF A PURINE-BASED CDK INHIBITOR WITH A TYROSINE KINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2010-01-06 | — | — | EP | claimed |
| WO-2008122779-A1 | COMBINATION OF A PURINE-BASED CDK INHIBITOR WITH A TYROSINE KINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2008-10-16 | — | — | WO | claimed |
| JP-2006506341-A | — | — | 2006-02-23 | — | — | JP | claimed |
| EP-1529047-A2 | NEW PURINE DERIVATIVES | Cyclacel Limited (GB) | 2005-05-11 | — | — | EP | claimed |
| WO-2004016612-A2 | NEW PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2004-02-26 | — | — | WO | claimed |
| US-9173938-B2 | Combination of a purine-based CDK inhibitor with a tyrosine kinase inhibitor and use thereof in the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-9173938-B2 | Combination of a purine-based CDK inhibitor with a tyrosine kinase inhibitor and use thereof in the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-8846696-B2 | Purine derivatives | CYCLACEL LIMITED (GB) | 2014-09-30 | — | — | US | disclosed |
| US-8846696-B2 | Purine derivatives | CYCLACEL LIMITED (GB) | 2014-09-30 | — | — | US | disclosed |
| US-8846696-B2 | Purine derivatives | CYCLACEL LIMITED (GB) | 2014-09-30 | — | — | US | disclosed |
| CN-101678029-B | Purine-based CDK inhibitors in combination with tyrosine kinase inhibitors and their use in the treatment of proliferative diseases | CYCLACEL LTD | 2012-07-18 | — | — | CN | disclosed |
| US-7582642-B2 | 4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol;antiproliferative agents; viricides; alopecia; strokes; central nervous system diorders; neurodegenerative diseases; antidiabetic agents; mitosis; cyclin dependent kinase inhibitors; protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2009-09-01 | — | — | US | disclosed |
| US-7582642-B2 | 4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol;antiproliferative agents; viricides; alopecia; strokes; central nervous system diorders; neurodegenerative diseases; antidiabetic agents; mitosis; cyclin dependent kinase inhibitors; protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2009-09-01 | — | — | US | disclosed |
| WO-2008122779-A1 | COMBINATION OF A PURINE-BASED CDK INHIBITOR WITH A TYROSINE KINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008122779-A1 | COMBINATION OF A PURINE-BASED CDK INHIBITOR WITH A TYROSINE KINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2008-10-16 | — | — | WO | disclosed |
| EP-1529047-B1 | NEW PURINE DERIVATIVES | CYCLACEL LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| EP-1529047-A2 | NEW PURINE DERIVATIVES | Cyclacel Limited (GB) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004016612-A2 | NEW PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143350-A1 | COMBINATION OF A PURINE-BASED CDK INHIBITOR WITH A TYROSINE KINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CDK4, CDK2, CDK3 | CDK2 2/4885CDK1 6/4885CDK4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.